SchizophreniaPhase 3ZENITHNCT01397786
Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia
A Phase 3 study testing OPC-34712 in people with Schizophrenia, run by Otsuka Pharmaceutical Development & Commercialization, Inc. at 148 sites in 19 countries.
Trial summary
The purpose of this study is to assess the long-term safety, tolerability and efficacy of oral OPC-34712 as monotherapy in adults with schizophrenia. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Schizophrenia
- What is being tested?
- OPC-34712
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,044 participants
- Where
- 148 sitesin 19 countries
- Study dates
- Sep 2011to Jan 2016
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male or female subjects between 18 and 65 years of age, with a diagnosis of schizophrenia, as defined by DSM-IV-TR criteria
- Outpatient status at last visit of Trial 331-10-230 or Trial 331-10-231
- Willing to discontinue all prohibitive psychotropic medications to meet protocol required washouts prior to and during the trial period.
- Other protocol specific inclusion criteria may apply.
Who cannot join
- Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving study drug
- Subjects with a current DSM-IV-TR Axis I diagnosis of:
- Schizoaffective disorder
- MDD
- Bipolar disorder
- Delirium, dementia, amnestic or other cognitive disorder
Show all 9Show fewer
- Borderline, paranoid, histrionic, schizotypal, schizoid or antisocial personality disorder
- Subjects presenting with a first episode of schizophrenia
- Other protocol specific exclusion criteria may apply.
Trial locations and contacts
148 sites in 19 countries.
148 sites in 19 countries
United States56 sites
Study site
Allentown, Pennsylvania, 18104
Study site
Anaheim, California, 92805
Study site
Austin, Texas, 78731
Study site
Austin, Texas, 78754
Study site
Birmingham, Alabama, 35226
Study site
Bradenton, Florida, 34208
Study site
Buffalo, New York, 14215
Study site
Cedarhurst, New York, 11516
Study site
Cerritos, California, 90703
Study site
Charleston, South Carolina, 29407
Study site
Chicago, Illinois, 60611
Study site
Dallas, Texas, 75231
Study site
Dallas, Texas, 75243
Study site
Dayton, Ohio, 45417
Study site
Escondido, California, 92025
Study site
Flowood, Mississippi, 39232
Study site
Garden Grove, California, 92845
Study site
Glendale, California, 91206
Study site
Hoffman Estates, Illinois, 60169
Study site
Houston, Texas, 77007
Study site
Jamaica, New York, 11432
Study site
Joliet, Illinois, 60435
Study site
Kirkland, Washington, 98033
Study site
Lake Charles, Louisiana, 70629
Study site
Las Vegas, Nevada, 89102
Study site
Leesburg, Florida, 34748
Study site
Little Rock, Arkansas, 72201
Study site
Little Rock, Arkansas, 72205
Study site
Long Beach, California, 90813
Study site
Maitland, Florida, 32751
Study site
Memphis, Tennessee, 38119
Study site
Miami, Florida, 33143
Study site
Miami Springs, Florida, 33166
Study site
National City, California, 91950
Study site
Norristown, Pennsylvania, 19403
Study site
North Miami, Florida, 33162
Study site
Oak Brook, Illinois, 60523
Study site
Oakland, California, 94612
Study site
Oceanside, California, 92056
Study site
Overland Park, Kansas, 66212
Study site
Pico Rivera, California, 90660
Study site
Richmond, Virginia, 23230
Study site
Rochester, New York, 14618
Study site
Saint Charles, Missouri, 63301
Study site
San Diego, California, 92102
Study site
San Diego, California, 92103
Study site
San Diego, California, 92123
Study site
Shreveport, Louisiana, 71104
Study site
Springdale, Arkansas, 72764
Study site
St Louis, Missouri, 63109
Study site
St Louis, Missouri, 63141
Study site
Staten Island, New York, 10305
Study site
Staten Island, New York, 10312
Study site
Tampa, Florida, 33613
Study site
Torrance, California, 90502
Study site
Washington D.C., District of Columbia, 20016
Russia15 sites
Study site
Arkhangelsk, 163530
Study site
Moscow, 117152
Study site
Moscow, 119435
Study site
Moscow Region, 142601
Study site
Nizhny Novgorod, 603155
Study site
Petrozavodsk, 185000
Study site
Saint Petersburg, 190005
Study site
Saint Petersburg, 190121
Study site
Saint Petersburg, 192019
Study site
Saint Petersburg, 194214
Study site
Saint Petersburg, 197341
Study site
Samara, 443016
Study site
Saratov, 410060
Study site
Tomsk, 634014
Study site
Village Nikolskoe, 188357
Ukraine12 sites
Study site
Chernihiv, 14000
Study site
Dnipropetrovsk, 49027
Study site
Dnipropetrovsk, 49115
Study site
Hlevakha, 08631
Study site
Kharkiv, 61068
Study site
Kherson, Vil. Stepanivka, 73488
Study site
Kyiv, 02660
Study site
Kyiv, 04080
Study site
Lviv, 79021
Study site
Odesa, 65014
Study site
Simferopol, 95006
Study site
Vinnytsia, 21005
Romania11 sites
Study site
Arad, 310022
Study site
Brasov, 500123
Study site
Bucharest, 010825
Study site
Bucharest, 030442
Study site
Bucharest, 041914
Study site
Cluj-Napoca, 400012
Study site
Craiova, 200473
Study site
Focşani, 620165
Study site
Iași, 700282
Study site
Piteşti, 110069
Study site
Targoviste, 130086
Malaysia6 sites
Study site
Ipoh, 31250
Study site
Jalan Greentown, 30450
Study site
Kajang, Selangor, 43000
Study site
Kota Bharu, Kelantan, 15586
Study site
Kuala Lumpur, Kuala Lumpur, 59100
Study site
Sabak Bernam, 88815
Latvia5 sites
Study site
Daugavpils, LV-5417
Study site
Jelgava, LV-3008
Study site
Liepāja, LV-3401
Study site
Riga, LV-1005
Study site
Strenči, LV-4730
South Korea5 sites
Study site
Incheon, 400-711
Study site
Incheon, 405-760
Study site
Seoul, 136-705
Study site
Seoul, 137-710
Study site
Seoul, 143-711
Colombia4 sites
Study site
Barranquilla, 00000
Study site
Bello, 00000
Study site
Bogotá, 00000
Study site
Pereira, 00000
Japan4 sites
Study site
Fujisawa-shi, Kanagawa, 251-8530
Study site
Kumamoto, Kumamoto, 861-8002
Study site
Kunigami-gun, Okinawa, 904-1201
Study site
Sakai-shi, Osaka, 590-0018
Poland4 sites
Study site
Choroszcz, 16-070
Study site
Gdansk, 80-282
Study site
Gdansk, 80-952
Study site
Lodz, 91-229
Serbia4 sites
Study site
Belgrade, 11000
Study site
Kragujevac, 34000
Study site
Novi Kneževac, 23330
Study site
Novi Sad, 21000
Slovakia4 sites
Study site
Bratislava, 82606
Study site
Michalovce, 07101
Study site
Rimavská Sobota, 97912
Study site
Rožňava, 04801
Taiwan4 sites
Study site
Kashsiung, 802
Study site
New Taipei City, 249
Study site
Taipei, 110
Study site
Taoyuan County, 333
Mexico3 sites
Study site
Col. Florida, Mexico City, 01030
Study site
Monterrey, Nuevo León, 64060
Study site
San Luis Potosí City, San Luis Potos, 78218
Philippines3 sites
Study site
Cebu City, 6000
Study site
Davao City, 8000
Study site
Manila, 1000
Canada2 sites
Study site
Burlington, Ontario, L7R 4E2
Study site
Chatham, Ontario, N7M 5L9
Turkey (Türkiye)2 sites
Study site
Diyarbakır, 21280
Study site
Kocaeli, 41380
About this study
Official title: A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia
The purpose of this study is to assess the long-term safety, tolerability and efficacy of oral OPC-34712 as monotherapy in adults with schizophrenia.
Read the detailed description
Schizophrenia is a severely debilitating mental illness that affects approximately 1% of the world population. Hallucinations and delusions are the most striking characteristic positive symptoms of schizophrenia; however, more subtle negative symptoms (eg, social withdrawal and lack of emotion, energy, and motivation) may also be present. The first antipsychotics developed for the treatment of schizophrenia were effective against positive symptoms, but showed little efficacy for negative symptoms and were also associated with a high incidence of side effects. Second generation antipsychotics, represent a significant advancement in the treatment of psychotic disorders because they are effective and at the same time exhibit fewer side effects than first generation antipsychotics. Although generally safer than first generation antipsychotics, the second-generation antipsychotics are not devoid of undesirable side effects such as Hyperprolactinemia and weight gain. In addition, the safety of these drugs vary considerably.
- Conditions
- Schizophrenia
- Being tested
- OPC-34712
- Medical subject headings
- Schizophrenia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
OPC-34712Drug
Phase A: 1-2 mgs/day by mouth, max of 4 wks.
Phase B: 1-4 mgs/day by mouth, up to 52 weeks
| Study group | Role | What they receive |
|---|---|---|
| OPC-34712 | Experimental | Not described Receives: Drug: OPC-34712 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants With Adverse Events (AEs)
A treatment-emergent adverse event (TEAE) is defined as an AE that started after start of investigational medicinal product (IMP) treatment; or if the event was continuous from baseline and was serious, IMP-related, or resulted in death, discontinuation, interruption or reduction of IMP.
Measured: From Baseline up to 52 Weeks
Secondary outcomes (14)
Mean Change From Baseline in Positive and Negative Syndrome Scale Total Score
The PANSS consisted of 3 subscales with 30 symptom constructs (positive subscale (7): delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/perseckion, and hostility; negative subscale (7): blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and conversation flow, stereotyped thinking and general psychopathology subscale (16): somatic concern, anxiety, guilt feelings, tension, mannerisms and posturing, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgment and insight, disturbance of volition, poor impulse control, preoccupation, and active social avoidance). Severity was rated on 7-point scale with scores 1 (absence) \& 7 (extremely severe). The PANSS total score was sum of rating scores for 7 positive, 7 negative, and 16 general psychopathology subscale items of PANSS panel.
Measured: From Baseline up to 52 Weeks
Mean Change From Baseline in PANSS Positive Subscale Score
The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. In positive subscale, the 7 positive symptom constructs were: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility.
Measured: From Baseline up to 52 Weeks
Mean Change From Baseline in PANSS Negative Subscale Score
The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. In negative subscale the severity was rated for the following 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking.
Measured: From Baseline up to 52 Weeks
Mean Change From Baseline in Clinical Global Impression - Severity of Illness Scale Score
The severity of illness for each participant was rated using the CGI-S. To perform this assessment, the investigator were to answer the following question: "Considering your total clinical experience with this particular population, how mentally ill was the participant at that time?" Response choices include: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.
Measured: From Baseline up to 52 Weeks
Mean Change From Baseline in Personal and Social Performance Scale Total Score
The PSP was a validated clinician-rated scale that measured personal and social functioning in four domains: socially useful activities (e.g, work and study), personal and social relationships, self-care, and disturbing and aggressive behaviors. Impairment in each of these domains was rated as absent, mild, manifest, marked, severe, or very severe. These ratings were then converted to a total score based on a 100-point scale using algorithms to identify the appropriate 10-point interval, and the rater's judgment that determined the total score within the 10-point interval. Participants with a PSP total score of 71 to 100 were considered to have mild functional difficulty. Scores of 31 to 70 represented manifest disabilities of various degrees and ratings of 1 to 30 indicated minimal functioning that required intense support and/or supervision.
Measured: From Baseline up to 52 Weeks
Mean Clinical Global Impression - Improvement Score
The efficacy of study medication was rated for each participant using the CGI-I. The investigator rated the participant's total improvement whether or not it was due to the drug treatment. All responses were compared to the participant's condition at Screening/Baseline (i.e, Week 6 visit of Protocol NCT00905307). Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.
Measured: From Baseline up to 52 Weeks
Response Rate
Response rate was defined as a reduction of ≥ 30% from Baseline in PANSS total score or CGI-I score of 1 (very much improved) or 2 (much improved) at the Last Visit.
Measured: From Baseline up to 52 Weeks
Discontinuation Rate for Lack of Efficacy
Discontinuation rate for the participants who discontinued due to lack of efficacy were examined.
Measured: From Baseline up to 52 Weeks
Mean Change From Baseline in Positive and Negative Syndrome Scale Excited Component Score
The PEC score consisted of five PANSS items: excitement (P4), hostility (P7), tension (G4), uncooperativeness (G8), and poor impulse control (G14). Each of the items were rated on a scale of 1 (absent) to 7 (extreme). The PEC scores ranged from 5 (not present) to 35 (extremely severe).
Measured: From Baseline up to 52 Weeks
Mean Change From Baseline in PANSS Marder Factor Scores - Positive Symptoms Score
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The positive factor score was the sum of the 8 components (delusions (P1), hallucinatory behavior (P3), grandiosity (P5), suspiciousness/persecution (P6), stereotyped thinking (N7), somatic concern (G1), unusual thought content (G9) and lack of judgment and insight (G12)) of the positive symptoms scale (range: 8 - best possible outcome to 56 - worst possible outcome).
Measured: From Baseline up to 52 Weeks
Mean Change From Baseline in PANSS Marder Factor Scores - Negative Symptoms Score
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The negative factor score is the sum of the 7 items (blunted affect (N1), emotional withdrawal (N2), poor rapport (N3), passive/apathetic social withdrawal (N4), lack of spontaneity and conversation flow (N6), motor retardation (G7) and active social avoidance (G16)) of the negative subscale (range: 8 - best possible outcome to 56 - worst possible outcome).
Measured: From Baseline up to 52 Weeks
Mean Change From Baseline in PANSS Marder Factor Scores - Disorganized Thought Score
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The disorganized thoughts factor score is the sum of score from the 7 items (conceptual disorganization (P2), difficulty in abstract thinking (N5), mannerisms and posturing (G5), disorientation (G10), poor attention (G11), disturbance of volition (G13) and preoccupation (G15)) on the disorganized thoughts subscale (range: 7 - best possible outcome to 49 - worst possible outcome).
Measured: From Baseline up to 52 Weeks
Mean Change From Baseline in PANSS Marder Factor Scores - Hostility/ Excitement Score
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The uncontrolled hostility/excitement factor score is the sum of score from the 4 items (excitement (P4), hostility (P7), uncooperativeness (G8) and poor impulse control (G14)) on the uncontrolled hostility/excitement subscale (range: 4 - best possible outcome to 28 - worst possible outcome).
Measured: From Baseline up to 52 Weeks
Mean Change From Baseline in PANSS Marder Factor Scores - Anxiety/Depression Score
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The anxiety/depression factor score is the sum of score from the 4 items (anxiety (G2), guilt feelings (G3), tension (G4) and depression (G6)) on the anxiety/depression subscale (range: 4 - best possible outcome to 28 - worst possible outcome).
Measured: From Baseline up to 52 Weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Jul 2011 (estimated)
- Study startSep 2011
- Primary completionJan 2016
- Study completionJan 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for SchizophreniaStudies of the same condition, open and under way.
- More trials run by Otsuka Pharmaceutical Development & Commercialization, Inc.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 1,044 participants (actual)
Sponsor and investigators
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Aleksandar Skuban, M.D., Study director, Otsuka Pharmaceutical Development & Commercialization, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01397786
- Sponsor's protocol ID
- 331-10-237
- Acronym
- ZENITH
- Status last verified
- Apr 2017
- First submitted
- 11 Jul 2011
- Last updated
- 10 May 2017
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Publications
Citrome L, Farovik A, Palma AM, Yildirim M. Effects of Brexpiprazole on Functioning in Patients With Schizophrenia Who Have Hostility and Agitation Symptoms: Post Hoc Analysis of Short- and Long-Term Trials. J Clin Psychiatry. 2026 Jul 20;87(3):26m16448. doi: 10.4088/JCP.26m16448.
PubMed 42474330Correll CU, He Y, Therrien F, MacKenzie E, Meehan SR, Weiss C, Hefting N, Hobart M. Effects of Brexpiprazole on Functioning in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies. J Clin Psychiatry. 2022 Mar 1;83(2):20m13793. doi: 10.4088/JCP.20m13793.
PubMed 35235720Marder SR, Meehan SR, Weiss C, Chen D, Hobart M, Hefting N. Effects of Brexpiprazole Across Symptom Domains in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies. Schizophr Bull Open. 2021 May 1;2(1):sgab014. doi: 10.1093/schizbullopen/sgab014. eCollection 2021 Jan.
PubMed 34901863Newcomer JW, Eriksson H, Zhang P, Weiller E, Weiss C. Changes in metabolic parameters and body weight in brexpiprazole-treated patients with acute schizophrenia: pooled analyses of phase 3 clinical studies. Curr Med Res Opin. 2018 Dec;34(12):2197-2205. doi: 10.1080/03007995.2018.1498779. Epub 2018 Jul 27.
PubMed 29985680Forbes A, Hobart M, Ouyang J, Shi L, Pfister S, Hakala M. A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia. Int J Neuropsychopharmacol. 2018 May 1;21(5):433-441. doi: 10.1093/ijnp/pyy002.
PubMed 29415258Kane JM, Skuban A, Hobart M, Ouyang J, Weiller E, Weiss C, Correll CU. Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophr Res. 2016 Jul;174(1-3):93-98. doi: 10.1016/j.schres.2016.04.013. Epub 2016 May 14.
PubMed 27188270
Study at a glance
From the registry record, last updated by the sponsor on 10 May 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia
- ClinicalTrials.gov ID
- NCT01397786
- Acronym / sponsor ID
- ZENITH / 331-10-237
- Conditions
- Schizophrenia
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1,044 participants (actual)
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Industry (pharma, biotech, devices)
- Study start
- Sep 2011
- Primary completion
- Jan 2016 (actual)
- Study completion
- Jan 2016 (actual)
- First posted
- 20 Jul 2011 (estimated)
- Results
- Posted 27 Mar 2017
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to assess the long-term safety, tolerability and efficacy of oral OPC-34712 as monotherapy in adults with schizophrenia.
Detailed description
Schizophrenia is a severely debilitating mental illness that affects approximately 1% of the world population. Hallucinations and delusions are the most striking characteristic positive symptoms of schizophrenia; however, more subtle negative symptoms (eg, social withdrawal and lack of emotion, energy, and motivation) may also be present. The first antipsychotics developed for the treatment of schizophrenia were effective against positive symptoms, but showed little efficacy for negative symptoms and were also associated with a high incidence of side effects. Second generation antipsychotics, represent a significant advancement in the treatment of psychotic disorders because they are effective and at the same time exhibit fewer side effects than first generation antipsychotics. Although generally safer than first generation antipsychotics, the second-generation antipsychotics are not devoid of undesirable side effects such as Hyperprolactinemia and weight gain. In addition, the safety of these drugs vary considerably.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| OPC-34712 | Experimental | Drug: OPC-34712 |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Male or female subjects between 18 and 65 years of age, with a diagnosis of schizophrenia, as defined by DSM-IV-TR criteria
- Outpatient status at last visit of Trial 331-10-230 or Trial 331-10-231
- Willing to discontinue all prohibitive psychotropic medications to meet protocol required washouts prior to and during the trial period.
- Other protocol specific inclusion criteria may apply.
Key exclusion criteria (9 listed)
- Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving study drug
- Subjects with a current DSM-IV-TR Axis I diagnosis of:
- Subjects presenting with a first episode of schizophrenia
- Other protocol specific exclusion criteria may apply.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| OPC-34712Phase A: 1-2 mgs/day by mouth, max of 4 wks. Phase B: 1-4 mgs/day by mouth, up to 52 weeks | Drug | OPC-34712 |
Primary outcome
Percentage of Participants With Adverse Events (AEs)
Time frame: From Baseline up to 52 Weeks
A treatment-emergent adverse event (TEAE) is defined as an AE that started after start of investigational medicinal product (IMP) treatment; or if the event was continuous from baseline and was serious, IMP-related, or resulted in death, discontinuation, interruption or reduction of IMP.
14 secondary outcomes
Mean Change From Baseline in Positive and Negative Syndrome Scale Total Score
Time frame: From Baseline up to 52 Weeks
Mean Change From Baseline in PANSS Positive Subscale Score
Time frame: From Baseline up to 52 Weeks
Mean Change From Baseline in PANSS Negative Subscale Score
Time frame: From Baseline up to 52 Weeks
Mean Change From Baseline in Clinical Global Impression - Severity of Illness Scale Score
Time frame: From Baseline up to 52 Weeks
Mean Change From Baseline in Personal and Social Performance Scale Total Score
Time frame: From Baseline up to 52 Weeks
Mean Clinical Global Impression - Improvement Score
Time frame: From Baseline up to 52 Weeks
Response Rate
Time frame: From Baseline up to 52 Weeks
Discontinuation Rate for Lack of Efficacy
Time frame: From Baseline up to 52 Weeks
Mean Change From Baseline in Positive and Negative Syndrome Scale Excited Component Score
Time frame: From Baseline up to 52 Weeks
Mean Change From Baseline in PANSS Marder Factor Scores - Positive Symptoms Score
Time frame: From Baseline up to 52 Weeks
Mean Change From Baseline in PANSS Marder Factor Scores - Negative Symptoms Score
Time frame: From Baseline up to 52 Weeks
Mean Change From Baseline in PANSS Marder Factor Scores - Disorganized Thought Score
Time frame: From Baseline up to 52 Weeks
Mean Change From Baseline in PANSS Marder Factor Scores - Hostility/ Excitement Score
Time frame: From Baseline up to 52 Weeks
Mean Change From Baseline in PANSS Marder Factor Scores - Anxiety/Depression Score
Time frame: From Baseline up to 52 Weeks
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 May 2017.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 42474330Citrome L, Farovik A, Palma AM, Yildirim M. Effects of Brexpiprazole on Functioning in Patients With Schizophrenia Who Have Hostility and Agitation Symptoms: Post Hoc Analysis of Short- and Long-Term Trials. J Clin Psychiatry. 2026 Jul 20;87(3):26m16448. doi: 10.4088/JCP.26m16448.
- Derived from this study: PubMed 35235720Correll CU, He Y, Therrien F, MacKenzie E, Meehan SR, Weiss C, Hefting N, Hobart M. Effects of Brexpiprazole on Functioning in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies. J Clin Psychiatry. 2022 Mar 1;83(2):20m13793. doi: 10.4088/JCP.20m13793.
- Derived from this study: PubMed 34901863Marder SR, Meehan SR, Weiss C, Chen D, Hobart M, Hefting N. Effects of Brexpiprazole Across Symptom Domains in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies. Schizophr Bull Open. 2021 May 1;2(1):sgab014. doi: 10.1093/schizbullopen/sgab014. eCollection 2021 Jan.
- Derived from this study: PubMed 29985680Newcomer JW, Eriksson H, Zhang P, Weiller E, Weiss C. Changes in metabolic parameters and body weight in brexpiprazole-treated patients with acute schizophrenia: pooled analyses of phase 3 clinical studies. Curr Med Res Opin. 2018 Dec;34(12):2197-2205. doi: 10.1080/03007995.2018.1498779. Epub 2018 Jul 27.
- Derived from this study: PubMed 29415258Forbes A, Hobart M, Ouyang J, Shi L, Pfister S, Hakala M. A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia. Int J Neuropsychopharmacol. 2018 May 1;21(5):433-441. doi: 10.1093/ijnp/pyy002.
- Derived from this study: PubMed 27188270Kane JM, Skuban A, Hobart M, Ouyang J, Weiller E, Weiss C, Correll CU. Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophr Res. 2016 Jul;174(1-3):93-98. doi: 10.1016/j.schres.2016.04.013. Epub 2016 May 14.
Related trials for Schizophrenia
RecruitingPhase 3
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
Schizophrenia, Autism-Related Irritability
Not yet recruiting
Deep Brain Stimulation for Treatment-Resistant Schizophrenia
Treatment Resistant Disorders
Not yet recruitingObservational study
Sleep Monitoring for Early Detection of Relapse in People With Schizophrenia or Bipolar Disorder Receiving Usual Treatment
Bipolar Disorder (BD), SCHIZOPHRENIA 1 (Disorder)
Not yet recruitingPhase 1
Pharmacokinetics and Relative Bioavailability of Intranasal vs Intramuscular Olanzapine in Healthy Adult Participants
Healthy Adult Participants
Active, not recruiting
Designing and Evaluating a Classroom-Based Mental Health Programme for Adolescents.
Mental Health Promotion
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Aleksandar Skuban, M.D. study director
Otsuka Pharmaceutical Development & Commercialization, Inc.
148 sites in 19 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing OPC-34712 in people with Schizophrenia, run by Otsuka Pharmaceutical Development & Commercialization, Inc. at 148 sites in 19 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 May 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 148 sites in United States, Russia, Ukraine, Romania, Malaysia and 14 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 27 Mar 2017). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants With Adverse Events (AEs) (time frame: From Baseline up to 52 Weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01397786, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 May 2017.